US5985354A
(en)
*
|
1995-06-07 |
1999-11-16 |
Brown University Research Foundation |
Preparation of multiwall polymeric microcapsules from hydrophilic polymers
|
US5997859A
(en)
*
|
1988-03-21 |
1999-12-07 |
Chiron Corporation |
Method for treating a metastatic carcinoma using a conditionally lethal gene
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US6569679B1
(en)
|
1988-03-21 |
2003-05-27 |
Chiron Corporation |
Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
|
US6133029A
(en)
*
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
DE69032841T2
(de)
*
|
1989-01-23 |
1999-05-12 |
Chiron Corp., Emeryville, Calif. |
Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
|
US5698531A
(en)
|
1989-03-31 |
1997-12-16 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
US5328470A
(en)
†
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
US5538722A
(en)
*
|
1989-06-13 |
1996-07-23 |
Stanford University |
Isolation, growth, differentiation and genetic engineering of human muscle cells
|
ATE162219T1
(de)
|
1989-11-16 |
1998-01-15 |
Univ Duke |
Transformation von tierischen hautzellen mit hilfe von partikeln
|
US6090790A
(en)
|
1989-12-14 |
2000-07-18 |
Eriksson; Elof |
Gene delivery by microneedle injection
|
US5661132A
(en)
*
|
1989-12-14 |
1997-08-26 |
Auragen, Inc. |
Wound healing
|
US5697901A
(en)
*
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US5817491A
(en)
*
|
1990-09-21 |
1998-10-06 |
The Regents Of The University Of California |
VSV G pseusdotyped retroviral vectors
|
FR2676072B1
(fr)
*
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
AU2143992A
(en)
*
|
1991-08-16 |
1993-03-16 |
Vical, Inc. |
Composition and method for treating cystic fibrosis
|
FR2681786A1
(fr)
*
|
1991-09-27 |
1993-04-02 |
Centre Nat Rech Scient |
Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
|
US6743623B2
(en)
|
1991-09-27 |
2004-06-01 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
US6099831A
(en)
*
|
1992-09-25 |
2000-08-08 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
AU671971B2
(en)
*
|
1991-11-29 |
1996-09-19 |
Chiron Corporation |
Anti-cancer immunotherapeutic vector constructs
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
WO1993012240A1
(en)
|
1991-12-17 |
1993-06-24 |
The Regents Of The University Of California |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
|
US6627615B1
(en)
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
WO1993015185A1
(en)
|
1992-01-27 |
1993-08-05 |
North Carolina State University |
GENE TRANSFER IN POULTRY BY INTRODUCTION OF EMBRYO CELLS $i(IN OVO)
|
CA2117429A1
(en)
|
1992-01-27 |
1993-08-05 |
James N. Petitte |
Gene transfer in birds by introduction of dna into muscle in ovo
|
US6297048B1
(en)
|
1992-02-04 |
2001-10-02 |
Chiron Corporation |
Hepatitis therapeutics
|
US5643578A
(en)
|
1992-03-23 |
1997-07-01 |
University Of Massachusetts Medical Center |
Immunization by inoculation of DNA transcription unit
|
US6165993A
(en)
*
|
1992-03-23 |
2000-12-26 |
University Of Massachusetts Medical Center |
DNA vaccines against rotavirus infections
|
US5620896A
(en)
*
|
1992-03-23 |
1997-04-15 |
University Of Massachusetts Medical Center |
DNA vaccines against rotavirus infections
|
US6174666B1
(en)
*
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US6806084B1
(en)
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
WO1993024640A2
(en)
*
|
1992-06-04 |
1993-12-09 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
US6936464B1
(en)
|
1992-10-02 |
2005-08-30 |
Cancer Research Technology Limited |
Immune responses to fusion proteins
|
US5981505A
(en)
*
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
NZ262582A
(en)
|
1993-01-26 |
1997-10-24 |
David B Weiner |
Compositions and methods for delivery of genetic material
|
US7001759B1
(en)
|
1993-01-26 |
2006-02-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
ATE420193T1
(de)
*
|
1993-01-26 |
2009-01-15 |
Univ Pennsylvania |
Zusammensetzung zur verabreichung genetischen materials
|
IL108915A0
(en)
*
|
1993-03-18 |
1994-06-24 |
Merck & Co Inc |
Polynucleotide vaccine against influenza virus
|
US5591601A
(en)
*
|
1993-05-14 |
1997-01-07 |
Ohio University Edison Animal Biotechnology Institute |
DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
|
EP1624068A1
(en)
*
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetic immunization with cationic lipids
|
US5679647A
(en)
*
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
US5849719A
(en)
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
EP0714308A4
(en)
*
|
1993-08-26 |
1998-07-29 |
Univ California |
METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES
|
US5985847A
(en)
*
|
1993-08-26 |
1999-11-16 |
The Regents Of The University Of California |
Devices for administration of naked polynucleotides which encode biologically active peptides
|
US5804566A
(en)
*
|
1993-08-26 |
1998-09-08 |
The Regents Of The University Of California |
Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
|
DE69435224D1
(de)
|
1993-09-15 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Rekombinante Alphavirus-Vektoren
|
US6348449B1
(en)
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
CA2158936C
(en)
|
1993-11-18 |
2012-02-21 |
Jack R. Barber |
Compositions and methods for utilizing conditionally lethal genes
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
EP0740704A1
(en)
*
|
1994-01-27 |
1996-11-06 |
University Of Massachusetts Medical Center |
Immunization by inoculation of dna transcription unit
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
GB9406498D0
(en)
*
|
1994-03-31 |
1994-05-25 |
Smithkline Beecham Biolog |
Novel compounds
|
US5739118A
(en)
*
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
AU2585395A
(en)
|
1994-05-09 |
1995-11-29 |
Chiron Corporation |
Retroviral vectors having a reduced recombination rate
|
GB9409985D0
(en)
*
|
1994-05-18 |
1994-07-06 |
Medical Res Council |
Vaccine against mycobacterial infections
|
WO1995033835A1
(en)
|
1994-06-02 |
1995-12-14 |
Chiron Corporation |
Nucleic acid immunization using a virus-based infection/transfection system
|
IL113817A
(en)
*
|
1994-06-30 |
2001-03-19 |
Merck & Co Inc |
Polynucleotide for vaccination against the umbilical cord virus
|
US7094767B2
(en)
|
1994-07-22 |
2006-08-22 |
Merck & Co., Inc. |
Polynucleotide herpes virus vaccine
|
IL114576A0
(en)
*
|
1994-07-22 |
1995-11-27 |
Merck & Co Inc |
Polynucleotide herpes virus vaccine
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
US5736524A
(en)
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
AU4740096A
(en)
*
|
1994-12-30 |
1996-07-24 |
Chiron Viagene, Inc. |
Direct administration of gene delivery vehicles at multiple sites
|
US6040295A
(en)
|
1995-01-13 |
2000-03-21 |
Genemedicine, Inc. |
Formulated nucleic acid compositions and methods of administering the same for gene therapy
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
US6605274B1
(en)
|
1995-04-11 |
2003-08-12 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
US7422574B2
(en)
|
1995-05-19 |
2008-09-09 |
Applied Tissue Technologies, Llc |
Microseeding device for gene delivery by microneedle injection
|
US6019980A
(en)
|
1995-06-07 |
2000-02-01 |
Connaught Laboratories Limited |
Nucleic acid respiratory syncytial virus vaccines
|
US6083925A
(en)
*
|
1995-06-07 |
2000-07-04 |
Connaught Laboratories Limited |
Nucleic acid respiratory syncytial virus vaccines
|
US6017897A
(en)
*
|
1995-06-07 |
2000-01-25 |
Pasteur Merieux Connaught Canada |
Nucleic acid respiratory syncytial virus vaccines
|
US6121246A
(en)
*
|
1995-10-20 |
2000-09-19 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Method for treating ischemic tissue
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
AU717113B2
(en)
|
1995-11-09 |
2000-03-16 |
Health Protection Agency |
Microencapsulated DNA for vaccination and gene therapy
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6168918B1
(en)
|
1996-01-31 |
2001-01-02 |
American Home Products Corp. |
Method of detecting foreign DNA integrated in eukaryotic chromosomes
|
US5891718A
(en)
*
|
1996-03-27 |
1999-04-06 |
Vical Incorporated |
Tetracycline inducible/repressible systems
|
WO1997038087A2
(en)
|
1996-04-05 |
1997-10-16 |
Chiron Corporation |
Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
|
CN1131314C
(zh)
*
|
1996-04-29 |
2003-12-17 |
仁文有限公司 |
含有过敏原基因的重组真核载体及其应用
|
CA2254082C
(en)
|
1996-05-03 |
2012-09-11 |
Thomas Jefferson University |
Metastatic colorectal cancer vaccine
|
US5851804A
(en)
*
|
1996-05-06 |
1998-12-22 |
Apollon, Inc. |
Chimeric kanamycin resistance gene
|
JP2002500502A
(ja)
|
1996-06-11 |
2002-01-08 |
メルク エンド カンパニー インコーポレーテッド |
合成c型肝炎遺伝子
|
WO1998000554A1
(en)
|
1996-07-03 |
1998-01-08 |
Genetics Institute, Inc. |
Protease fmh-1, an ice/ced-like protease
|
DE69738640T2
(de)
*
|
1996-08-15 |
2009-07-16 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze
|
EP0961547A4
(en)
*
|
1996-08-23 |
2002-08-14 |
Univ North Carolina State |
NEUTRALIZATION SENSITIVE EPITROPE OF CRYPTOSPORIDIUM PARVUM
|
CN1138533C
(zh)
|
1996-09-13 |
2004-02-18 |
利普森有限公司 |
脂质体
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
CA2266656A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6225290B1
(en)
|
1996-09-19 |
2001-05-01 |
The Regents Of The University Of California |
Systemic gene therapy by intestinal cell transformation
|
US6228621B1
(en)
|
1996-10-23 |
2001-05-08 |
The Trustees Of The University Of Pennsylvania |
Plasmids encoding immunogenic proteins and intracellular targeting sequences
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6204250B1
(en)
|
1996-11-22 |
2001-03-20 |
The Mount Sinai Medical Center Of The City Of New York |
Immunization of infants
|
US20020082224A1
(en)
*
|
1997-01-14 |
2002-06-27 |
Douglas J. Jolly |
Non-immunogenic prodrugs and selectable markers for use in gene therapy
|
US6034072A
(en)
*
|
1997-02-10 |
2000-03-07 |
Genemedicine, Inc. |
IL-2 gene expression and delivery systems and uses
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
CA2285178A1
(en)
|
1997-03-25 |
1998-10-01 |
Morris Laster |
Bone marrow as a site for transplantation
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
EP1003531B1
(en)
|
1997-05-20 |
2007-08-22 |
Ottawa Health Research Institute |
Processes for preparing nucleic acid constructs
|
US7135333B1
(en)
|
1997-08-07 |
2006-11-14 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cancer cells and methods of using the same
|
US6348450B1
(en)
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
ES2167939T3
(es)
|
1997-08-13 |
2002-05-16 |
Biontex Lab Gmbh |
Nuevas poliaminas, su preparacion y usos.
|
FR2767337B1
(fr)
|
1997-08-14 |
2002-07-05 |
Pasteur Institut |
Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
|
US6818627B1
(en)
|
1997-08-14 |
2004-11-16 |
The Trustees Of The University Of Pennsylvania |
Functional fragments of HIV-1 Vpr protein and methods of using the same
|
WO1999013896A1
(en)
|
1997-09-18 |
1999-03-25 |
The Trustees Of The University Of Pennsylvania |
Attenuated vif dna immunization cassettes for genetic vaccines
|
US6517843B1
(en)
|
1999-08-31 |
2003-02-11 |
Merial |
Reduction of porcine circovirus-2 viral load with inactivated PCV-2
|
UA78180C2
(uk)
|
1997-10-03 |
2007-03-15 |
Меріаль |
Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
|
AU745805B2
(en)
|
1997-10-28 |
2002-04-11 |
Wyeth |
Compositions and methods for delivery of genetic material
|
US6914131B1
(en)
|
1998-10-09 |
2005-07-05 |
Chiron S.R.L. |
Neisserial antigens
|
CA2671261A1
(en)
|
1997-11-06 |
1999-05-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Neisserial antigens
|
EP1032428B1
(en)
|
1997-11-20 |
2003-06-18 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
EP2218730A1
(en)
|
1997-11-28 |
2010-08-18 |
Merck Serono Biodevelopment |
Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
US20040062775A1
(en)
|
1997-12-05 |
2004-04-01 |
Agence Francaise De Securite Sanitaire Des Aliments |
Circovirus sequences associated with piglet weight loss disease (PWD)
|
FR2772047B1
(fr)
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
|
DE69837934T2
(de)
|
1997-12-11 |
2008-02-21 |
University Of Saskatchewan, Saskatoon |
Multisystemisches kümmerwuchssyndrom durch viren in schweinen
|
EP1816200B1
(en)
|
1997-12-11 |
2016-03-09 |
Merial |
Postweaning multisystemic wasting syndrome virus for pigs
|
CA2315256A1
(en)
*
|
1997-12-16 |
1999-06-24 |
Valentis, Inc. |
Needle-free injection of formulated nucleic acid molecules
|
JP2002507387A
(ja)
|
1997-12-24 |
2002-03-12 |
コリクサ コーポレイション |
乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
EP2003201A3
(en)
|
1998-03-18 |
2008-12-31 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
JP2002506625A
(ja)
|
1998-03-19 |
2002-03-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
サイトカインレセプター共通γ鎖様
|
US6395253B2
(en)
|
1998-04-23 |
2002-05-28 |
The Regents Of The University Of Michigan |
Microspheres containing condensed polyanionic bioactive agents and methods for their production
|
EP2261338A3
(en)
|
1998-05-01 |
2012-01-04 |
Novartis Vaccines and Diagnostics, Inc. |
Neisseria meningitidis antigens and compositions
|
US6406719B1
(en)
|
1998-05-13 |
2002-06-18 |
Microbiological Research Authority |
Encapsulation of bioactive agents
|
GB9810236D0
(en)
|
1998-05-13 |
1998-07-08 |
Microbiological Res Authority |
Improvements relating to encapsulation of bioactive agents
|
CA2340330A1
(en)
|
1998-08-20 |
2000-03-02 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
|
US6693087B1
(en)
|
1998-08-20 |
2004-02-17 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding POMP91A protein of Chlamydia
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
DE69937964T2
(de)
|
1998-11-12 |
2009-01-02 |
Invitrogen Corp., Carlsbad |
Transportreagentien
|
US7148324B1
(en)
*
|
1998-12-14 |
2006-12-12 |
Dendreon Corporation |
Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
|
ATE408695T1
(de)
|
1998-12-16 |
2008-10-15 |
Novartis Vaccines & Diagnostic |
Menschliche cyclin-abhängige kinase (hpnqalre)
|
PT1141315E
(pt)
|
1998-12-31 |
2008-05-05 |
Novartis Vaccines & Diagnostic |
Polipéptidos do envelope (env) de hiv modificados
|
EP1141313A2
(en)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
AU2487300A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
US6664049B1
(en)
|
1999-01-20 |
2003-12-16 |
Aventis Pasteur S.A. |
Method and device for cell lysis
|
MXPA01007895A
(es)
|
1999-02-03 |
2003-07-21 |
Biosante Pharmaceuticals Inc |
Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2001077137A1
(en)
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6673601B1
(en)
|
1999-04-15 |
2004-01-06 |
Institut Pasteur |
Chimeric lyssavirus nucleic acids and polypeptides
|
EP1721982B1
(en)
|
1999-04-15 |
2013-04-10 |
Boehringer Ingelheim Vetmedica GmbH |
Chimeric lyssavirus nucleic acids and polypeptides
|
ATE464910T1
(de)
|
1999-04-30 |
2010-05-15 |
Univ Pennsylvania |
Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
|
ES2397918T3
(es)
|
1999-04-30 |
2013-03-12 |
Novartis Vaccines And Diagnostics S.R.L. |
Antígenos Neisseriales conservados
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6943152B1
(en)
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
DE19928342A1
(de)
*
|
1999-06-21 |
2000-12-28 |
Deutsches Krebsforsch |
Vektoren zur gentherapeutischen Tumorbehandlung
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
FR2797402B1
(fr)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
|
US6541458B1
(en)
|
1999-07-16 |
2003-04-01 |
Merial |
Feline calicivirus genes and vaccines in particular recombinant vaccines
|
FR2796396A1
(fr)
*
|
1999-07-16 |
2001-01-19 |
Merial Sas |
Gene de calicivirus felin et vaccin recombine les incorporant
|
FR2796397B1
(fr)
*
|
1999-07-16 |
2006-09-01 |
Merial Sas |
Genes de calicivirus felin et vaccins notamment vaccins recombines
|
ES2306670T3
(es)
|
1999-10-22 |
2008-11-16 |
Sanofi Pasteur Limited |
Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
|
CN101613397A
(zh)
|
1999-10-29 |
2009-12-30 |
启龙股份公司 |
奈瑟球菌的抗原性肽
|
CA2392103A1
(en)
|
1999-11-18 |
2001-05-25 |
Chiron Corporation |
Human fgf-21 gene and gene expression products
|
US6241710B1
(en)
|
1999-12-20 |
2001-06-05 |
Tricardia Llc |
Hypodermic needle with weeping tip and method of use
|
DE60039786D1
(de)
|
1999-12-22 |
2008-09-18 |
Univ Pennsylvania |
Kosmid-dns-konstrukte und verfahren für deren herstellung und verwendung
|
US6656706B2
(en)
|
1999-12-23 |
2003-12-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
|
IL150485A0
(en)
*
|
1999-12-28 |
2002-12-01 |
Novartis Ag |
Method of achieving persistent transgene expression
|
AU2406901A
(en)
*
|
2000-01-07 |
2001-07-16 |
Makoto Hatakeyama |
Method for expressing gene and use thereof
|
ES2507100T3
(es)
|
2000-01-17 |
2014-10-14 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacuna OMV suplementada contra meningococo
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US7078388B2
(en)
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
ES2299476T3
(es)
|
2000-02-28 |
2008-06-01 |
Novartis Vaccines And Diagnostics S.R.L. |
Expresion hibrida de proteinas de neisseria.
|
US6841362B1
(en)
|
2000-02-29 |
2005-01-11 |
The Trustees Of Columbia University In The City Of New York |
Melanoma differentiation associated gene-7 promoter and uses thereof
|
US7229822B1
(en)
|
2000-02-29 |
2007-06-12 |
Univ Columbia |
Melanoma differentation associated gene-5 and vectors and cells containing same
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
US6953658B2
(en)
|
2000-03-09 |
2005-10-11 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
|
ES2548381T3
(es)
|
2000-03-27 |
2015-10-16 |
Thomas Jefferson University |
Composiciones para el tratamiento e imágenes de células de cáncer estomacales y de esófago
|
EP1702983A3
(en)
|
2000-04-13 |
2007-01-10 |
Medical University of South Carolina |
Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
|
US7238672B1
(en)
|
2000-04-17 |
2007-07-03 |
Institut Pasteur |
Chimeric lyssavirus nucleic acids and polypeptides
|
AU2001257511A1
(en)
*
|
2000-05-03 |
2001-11-12 |
Joe D'silva |
Process and device for producing liquid dosage formulations
|
EP1792995A3
(en)
|
2000-05-08 |
2007-06-13 |
Sanofi Pasteur Limited |
Chlamydia secretory locus orf and uses thereof
|
AU5810201A
(en)
|
2000-05-10 |
2001-11-20 |
Aventis Pasteur |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
US6596526B1
(en)
|
2000-06-09 |
2003-07-22 |
Baxter Aktiengesellschaft |
Furin polypeptides with improved characteristics
|
EP1734050A3
(en)
|
2000-06-12 |
2012-12-05 |
University Of Saskatchewan |
Immunization of dairy cattle with GapC protein against streptococcus infection
|
DE60134275D1
(de)
|
2000-06-15 |
2008-07-10 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
WO2002000939A2
(en)
|
2000-06-28 |
2002-01-03 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating colon cancer
|
DE60131975T2
(de)
|
2000-07-27 |
2008-12-18 |
The Trustees Of The University Of Pennsylvania |
Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
|
ATE497007T1
(de)
|
2000-08-25 |
2011-02-15 |
Basf Plant Science Gmbh |
Polynukleotide, die für prenylproteasen aus pflanzen kodieren
|
US7829276B2
(en)
|
2000-09-18 |
2010-11-09 |
Thomas Jefferson University |
Methods of using CRCA-1 as a stomach and esophageal cancer marker
|
AU1412702A
(en)
|
2000-10-27 |
2002-05-06 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a and b
|
AU2002227365A1
(en)
|
2000-12-07 |
2002-06-18 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
DE60239317D1
(de)
|
2001-01-12 |
2011-04-14 |
Novartis Vaccines & Diagnostic |
Nukleinsäure mukosale immunisierung
|
AU2002250032B2
(en)
|
2001-02-09 |
2008-06-05 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
AT410634B
(de)
|
2001-02-21 |
2003-06-25 |
Franz X Dr Heinz |
Attenuierte lebendimpfstoffe
|
DE60219601T2
(de)
*
|
2001-02-22 |
2007-12-27 |
Opperbas Holding B.V. |
Durch liposome vermittelte dna verabreichung
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
WO2002094871A1
(en)
|
2001-05-24 |
2002-11-28 |
Human Dna Technology Inc |
Novel keratinocyte growth factor-2 analogue in hair follicle
|
US8216585B2
(en)
|
2001-05-25 |
2012-07-10 |
The Trustees Of The University Of Pennsylvania |
Targeted particles and methods of using the same
|
ATE456959T1
(de)
|
2001-06-05 |
2010-02-15 |
Curevac Gmbh |
Stabilisierte tumorantigen-mrna mit erhöhtem g/c- gehalt
|
CA2349506C
(en)
|
2001-06-14 |
2009-12-08 |
Duke University |
A method for selective expression of therapeutic genes by hyperthermia
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
EP2280074A3
(en)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
EP1409506B1
(en)
|
2001-07-23 |
2012-05-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for rnai mediated inhibition of gene expression in mammals
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
ES2386280T3
(es)
|
2001-08-09 |
2012-08-16 |
Giuseppe Intini |
Implantes de tejido y método para la preparación y utilización de los mismos
|
DE60230877D1
(de)
|
2001-08-15 |
2009-03-05 |
Univ Brown Res Found |
Behandlung von muskeldystrophien und verwandter erkrankungen
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
CA2458995C
(en)
|
2001-08-31 |
2013-04-30 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
AU2002343475A1
(en)
|
2001-10-03 |
2003-04-14 |
Selective Genetics, Inc. |
Traversal of nucleic acid molecules through a fluid space and expression in repair cells
|
AU2002359446B2
(en)
|
2001-11-09 |
2008-12-04 |
Georgetown University |
Novel isoforms of vascular endothelial cell growth inhibitor
|
EP2335724A1
(en)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisation against chlamydia trachomatis
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
DE60326931D1
(de)
|
2002-01-08 |
2009-05-14 |
Novartis Vaccines & Diagnostic |
In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
|
AU2003235707A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
FR2845918A1
(fr)
*
|
2002-10-16 |
2004-04-23 |
Pasteur Institut |
Preparations immunogenes et vaccinantes a base d'arn
|
WO2003080808A2
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
EP1356820A1
(en)
|
2002-04-26 |
2003-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
DNA vaccine combined with an inducer of tumor cell apoptosis
|
US20030206916A1
(en)
|
2002-05-03 |
2003-11-06 |
Rush-Presbyterian-St. Luke's Medical Center |
Immunogenic peptides
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
JP2006515162A
(ja)
|
2002-08-29 |
2006-05-25 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
環状核酸ベクター、ならびに同ベクターの作製法および使用法
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
SI2270048T1
(sl)
|
2002-12-24 |
2016-01-29 |
Rinat Neuroscience Corp. |
Protitelesa proti NGF-ju in postopki uporabe le-teh
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
AU2004213452A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
AU2004213044A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7812116B2
(en)
|
2003-07-03 |
2010-10-12 |
Rush University Medical Center |
Immunogenic peptides
|
EP1700121A4
(en)
|
2003-12-23 |
2008-09-03 |
Rinat Neuroscience Corp |
AGONIST ANTI-TRKC ANTIBODIES AND METHODS OF USE
|
AU2004308964B2
(en)
|
2003-12-23 |
2010-09-16 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of HPV and methods of their use
|
ES2344303T3
(es)
|
2004-02-13 |
2010-08-24 |
Nod Pharmaceuticals, Inc. |
Particulas que comprenden un nucleo de nanoparticulas de fosfato calcico, una biomolecula y un acido biliar, los metodos de produccion y el uso terapeutico de las mismas.
|
ES2407465T3
(es)
|
2004-03-29 |
2013-06-12 |
Galpharma Co., Ltd. |
Nueva proteína galectina 9 modificada y uso de la misma
|
CA2562024C
(en)
|
2004-04-07 |
2014-05-27 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
EP1747023B2
(en)
|
2004-05-04 |
2016-03-09 |
The Board of Trustees of The Leland Stanford Junior University |
Methods and compositions for reducing hcv viral genome amounts in a target cell
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
WO2006014422A2
(en)
|
2004-07-06 |
2006-02-09 |
The Trustees Of Columbia University In The City Of New York |
Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same
|
ES2622394T3
(es)
|
2004-07-09 |
2017-07-06 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glicoproteína g del virus hendra
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
KR20070040824A
(ko)
|
2004-07-30 |
2007-04-17 |
리나트 뉴로사이언스 코퍼레이션 |
아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
|
US7572600B2
(en)
|
2004-08-04 |
2009-08-11 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
WO2006050394A2
(en)
|
2004-11-01 |
2006-05-11 |
Novartis Vaccines And Diagnostics Inc. |
Combination approaches for generating immune responses
|
US20090041812A1
(en)
|
2004-11-01 |
2009-02-12 |
Bell Steve J D |
Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
|
CN101443452B
(zh)
|
2004-11-30 |
2013-03-27 |
梅瑞尔有限公司 |
用于细胞化学裂解的混合装置
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
WO2006077266A1
(en)
|
2005-01-24 |
2006-07-27 |
Laboratoires Serono S.A. |
Use of soluble cd164 variants in inflammatory and/or autoimmune disorders
|
CN101203529A
(zh)
|
2005-02-18 |
2008-06-18 |
诺华疫苗和诊断公司 |
来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
JP2008535853A
(ja)
|
2005-04-07 |
2008-09-04 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
癌関連遺伝子
|
US9119901B2
(en)
|
2005-04-28 |
2015-09-01 |
Warsaw Orthopedic, Inc. |
Surface treatments for promoting selective tissue attachment to medical impants
|
EP1907425B1
(en)
|
2005-07-22 |
2014-01-08 |
Y's Therapeutics Co., Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
CA2626253A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
KR20080068062A
(ko)
|
2005-11-14 |
2008-07-22 |
리나트 뉴로사이언스 코퍼레이션 |
칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
US8026354B2
(en)
|
2005-11-23 |
2011-09-27 |
Institut Pasteur |
Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
|
EP1803814A1
(en)
|
2005-12-27 |
2007-07-04 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Method of improving the antibody selection capacity in phage-display library
|
GB0606190D0
(en)
|
2006-03-28 |
2006-05-10 |
Isis Innovation |
Construct
|
KR101510753B1
(ko)
|
2006-06-07 |
2015-04-10 |
바이오얼라이언스 씨.브이. |
암세포 상에서 발현되는 cd-43 및 cea 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
|
EP2035035A2
(en)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Immunogenic compositions for streptococcus agalactiae
|
US8323815B2
(en)
|
2006-06-16 |
2012-12-04 |
Porous Power Technology, LLC |
Optimized microporous structure of electrochemical cells
|
US8227437B2
(en)
|
2006-06-22 |
2012-07-24 |
Tai June Yoo |
Restoration of hearing loss
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
US8202967B2
(en)
|
2006-10-27 |
2012-06-19 |
Boehringer Ingelheim Vetmedica, Inc. |
H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
|
DE102007001370A1
(de)
*
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
AU2008213999B2
(en)
|
2007-02-06 |
2014-04-17 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
WO2008116116A2
(en)
|
2007-03-20 |
2008-09-25 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
EP2155777A2
(en)
|
2007-04-10 |
2010-02-24 |
The Administrators of the Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
US8202983B2
(en)
|
2007-05-10 |
2012-06-19 |
Agilent Technologies, Inc. |
Thiocarbon-protecting groups for RNA synthesis
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US7855049B2
(en)
|
2007-08-31 |
2010-12-21 |
Biocrine Ab |
Inositol pyrophosphates determine exocytotic capacity
|
AU2008314486B2
(en)
|
2007-10-15 |
2014-06-26 |
Jingang Medicine (Australia) Pty Ltd |
Construct system and uses therefor
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
間質性膀胱炎の治療
|
AU2008338313B2
(en)
|
2007-12-18 |
2014-01-16 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
|
WO2009111088A2
(en)
*
|
2008-01-02 |
2009-09-11 |
The Johns Hopkins University |
Antitumor immunization by liposomal delivery of vaccine to the spleen
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
JP5546107B2
(ja)
*
|
2008-04-17 |
2014-07-09 |
国立大学法人宇都宮大学 |
RNAウイルスBmMLV陰性カイコ培養細胞株
|
CN102159713A
(zh)
|
2008-05-20 |
2011-08-17 |
Eos神经科学公司 |
用于递送光敏蛋白的载体和使用方法
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
EP4071169A2
(en)
|
2008-08-25 |
2022-10-12 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
US20130324478A1
(en)
|
2008-09-08 |
2013-12-05 |
Laurence Faure |
Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
CA2738019A1
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
WO2010054141A2
(en)
|
2008-11-06 |
2010-05-14 |
The Trustees Of Columbia University In The City Of New York |
Polynucleotides encoding a human trim-cyp fusion polypeptide, compositions thereof, and methods of using same
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP3549602A1
(en)
|
2009-03-06 |
2019-10-09 |
GlaxoSmithKline Biologicals S.A. |
Chlamydia antigens
|
EP2411519B1
(en)
|
2009-03-27 |
2015-07-22 |
Institut National de la Santé et de la Recherche Médicale |
Kanamycin antisense nucleic acid for the treatment of cancer
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8679505B2
(en)
|
2009-04-14 |
2014-03-25 |
Novartis Ag |
Compositions for immunising against Staphylococcus aureus
|
US9276246B2
(en)
|
2009-05-20 |
2016-03-01 |
Samsung Electronics Co., Ltd. |
Treatment and adhesive for microporous membranes
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
FR2947455B1
(fr)
|
2009-07-01 |
2014-01-03 |
Centre Nat Rech Scient |
La dermaseptine b2 comme inhibiteur de la croissance tumorale
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
AR078253A1
(es)
|
2009-09-02 |
2011-10-26 |
Boehringer Ingelheim Vetmed |
Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
|
GB0918679D0
(en)
|
2009-10-23 |
2009-12-09 |
Iqur Ltd |
Influenza vaccine
|
GB0918782D0
(en)
|
2009-10-26 |
2009-12-09 |
St Georges Hosp Medical School |
A protein as an adjuvant for a vaccine
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP3403647A1
(en)
*
|
2009-12-01 |
2018-11-21 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
AU2014250713B2
(en)
*
|
2009-12-01 |
2016-07-28 |
Translate Bio, Inc. |
Delivery Of mRNA For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
|
AU2016250459B2
(en)
*
|
2009-12-01 |
2018-06-28 |
Translate Bio, Inc. |
Delivery Of mRNA For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
|
TWI552760B
(zh)
|
2010-02-24 |
2016-10-11 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
SA111320266B1
(ar)
|
2010-03-11 |
2015-06-21 |
رينات نيوروساينس كوربوريشن |
أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
|
GB201004475D0
(en)
|
2010-03-17 |
2010-05-05 |
Isis Innovation |
Gene silencing
|
US9247720B2
(en)
|
2010-03-24 |
2016-02-02 |
Institut National de la Santé et de la Recherche Médicale |
Primate model from the family cercopithecidae infected by a HBV strain of human genotype
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9795658B2
(en)
|
2010-04-20 |
2017-10-24 |
Admedus Vaccines Pty Ltd |
Expression system for modulating an immune response
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
EP2383286A1
(en)
|
2010-04-30 |
2011-11-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of retinal degenerative diseases
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
US20130122033A1
(en)
|
2010-07-02 |
2013-05-16 |
Rita De Santis |
Fimh vaccine against urinary tract infections (uti)
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のrnaを用いた大型哺乳動物の免疫化
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
US9801897B2
(en)
|
2010-07-06 |
2017-10-31 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to trigger multiple immune pathways
|
JP2013533286A
(ja)
|
2010-07-30 |
2013-08-22 |
セントルイス ユニバーシティ |
疼痛を治療する方法
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
GB201014026D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
FI4066855T3
(fi)
|
2010-08-31 |
2023-03-23 |
Glaxosmithkline Biologicals Sa |
Pegyloituja liposomeja immunogeenia koodittavan rna:n kuljettamiseksi
|
DK4043040T3
(da)
|
2010-08-31 |
2023-03-20 |
Glaxosmithkline Biologicals Sa |
Små liposomer til afgivelse af immunogen-kodende RNA
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RU2597974C2
(ru)
|
2010-10-11 |
2016-09-20 |
Новартис Аг |
Платформы доставки антигенов
|
AR083533A1
(es)
|
2010-10-22 |
2013-03-06 |
Boehringer Ingelheim Vetmed |
Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
CA2823194A1
(en)
|
2010-12-27 |
2012-07-05 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
FR2972006B1
(fr)
|
2011-02-24 |
2016-03-25 |
Centre Nat Rech Scient |
Nouveaux fragments d'il-33 superactifs et leurs utilisations
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
US9540610B2
(en)
|
2011-04-28 |
2017-01-10 |
Warsaw Orthopedic, Inc. |
Collagen and cell implant
|
RU2013154295A
(ru)
|
2011-06-08 |
2015-07-20 |
Шир Хьюман Дженетик Терапис, Инк. |
КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
|
AR088028A1
(es)
|
2011-08-15 |
2014-05-07 |
Boehringer Ingelheim Vetmed |
Proteinas h5, de h5n1 para un uso medicinal
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
WO2013033092A2
(en)
|
2011-09-03 |
2013-03-07 |
Boehringer Ingelheim Vetmedica Gmbh |
Streptococcus suis pilus antigens
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
US8871908B2
(en)
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
RU2014123030A
(ru)
|
2011-12-22 |
2016-02-20 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013124477A1
(en)
|
2012-02-24 |
2013-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of retinal degenerative diseases
|
JP6216766B2
(ja)
|
2012-03-29 |
2017-10-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
クリック核酸
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
JP2015513912A
(ja)
|
2012-04-02 |
2015-05-18 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
タンパク質の産生のための修飾ポリヌクレオチド
|
HUE044612T2
(hu)
|
2012-05-04 |
2019-11-28 |
Pfizer |
Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek
|
WO2013185069A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
AU2013286866B2
(en)
|
2012-07-02 |
2018-03-01 |
Commonwealth Scientific And Industrial Research Organization |
Paramyxovirus and methods of use
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
AU2013312765A1
(en)
*
|
2012-09-06 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Cell selective proteome labeling
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
WO2014127825A1
(en)
|
2013-02-21 |
2014-08-28 |
Boehringer Ingelheim Vetmedica Gmbh |
H5 proteins of h5n1 influenza virus for use as a medicament
|
LT2968586T
(lt)
|
2013-03-14 |
2018-11-26 |
Translate Bio, Inc. |
Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
JP2016513682A
(ja)
|
2013-03-15 |
2016-05-16 |
ダイアックス コーポレーション |
抗血漿カリクレイン抗体
|
US9248189B2
(en)
|
2013-05-07 |
2016-02-02 |
Pfizer Inc. |
Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
|
CN105431457A
(zh)
|
2013-06-06 |
2016-03-23 |
大卫·J·罗兰 |
单结构域抗体展示
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
EP4050033A1
(en)
|
2013-08-02 |
2022-08-31 |
Pfizer Inc. |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
EP4091629A1
(en)
|
2013-09-25 |
2022-11-23 |
Zoetis Services LLC |
Pcv2b divergent vaccine composition and methods of use
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
AU2014329452B2
(en)
|
2013-10-03 |
2019-06-20 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EA201690590A1
(ru)
|
2013-10-22 |
2016-12-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ТЕРАПИЯ НЕДОСТАТОЧНОСТИ АРГИНИНОСУКЦИНАТ-СИНТЕТАЗЫ С ПОМОЩЬЮ мРНК
|
CA2928186A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
WO2015073580A1
(en)
|
2013-11-13 |
2015-05-21 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
DK3119431T3
(da)
|
2014-03-21 |
2024-03-18 |
Teva Pharmaceuticals Int Gmbh |
Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
|
CA2943816A1
(en)
|
2014-04-03 |
2015-10-08 |
Boehringer Ingelheim Vetmedica, Inc. |
Porcine epidemic diarrhea virus vaccine
|
EP3134131B1
(en)
|
2014-04-23 |
2021-12-22 |
ModernaTX, Inc. |
Nucleic acid vaccines
|
EP3134546A4
(en)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
CN106572974B
(zh)
|
2014-07-15 |
2021-04-23 |
生命技术公司 |
用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
|
EP3204516B1
(en)
|
2014-10-06 |
2023-04-26 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
JP6941561B2
(ja)
|
2014-10-09 |
2021-09-29 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
免疫障害を処置するための複数の可変il−2用量レジメン
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
MY196625A
(en)
|
2015-04-13 |
2023-04-23 |
Pfizer |
Therapeutic Antibodies and Their Uses
|
AU362291S
(en)
|
2015-05-08 |
2015-06-15 |
|
Extrusion
|
AU362290S
(en)
|
2015-05-08 |
2015-06-15 |
|
Extrusion
|
EP3313863B1
(en)
|
2015-06-29 |
2020-12-23 |
The Board of Trustees of the Leland Stanford Junior University |
Degron fusion constructs and methods for controlling protein production
|
JP7068160B2
(ja)
|
2015-07-21 |
2022-05-16 |
武田薬品工業株式会社 |
第XIIa因子のモノクローナル抗体阻害剤
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
TW201718638A
(zh)
|
2015-07-21 |
2017-06-01 |
現代治療公司 |
傳染病疫苗
|
US10877045B2
(en)
|
2015-07-21 |
2020-12-29 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
IL302353A
(en)
|
2015-08-19 |
2023-06-01 |
Pfizer |
TFPI inhibitory antibodies and their uses
|
DK3344289T3
(da)
|
2015-08-31 |
2020-04-14 |
Boehringer Ingelheim Vetmedica Gmbh |
Pestivirusvacciner mod medfødt tremor
|
EP3922645A1
(en)
|
2015-09-15 |
2021-12-15 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
CA2996613A1
(en)
|
2015-09-16 |
2017-03-23 |
Boehringer Ingelheim Vetmedica, Inc. |
Salmonella choleraesuis-salmonella typhimurium vaccines
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
HUE059127T2
(hu)
|
2015-10-22 |
2022-10-28 |
Modernatx Inc |
Légúti vírusok elleni vakcinák
|
MA46316A
(fr)
|
2015-10-22 |
2021-03-24 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
PE20181529A1
(es)
|
2015-10-22 |
2018-09-26 |
Modernatx Inc |
Vacunas de acido nucleico para el virus varicela-zoster (vzv)
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
JP2018531290A
(ja)
|
2015-10-22 |
2018-10-25 |
モデルナティーエックス, インコーポレイテッド |
性感染症ワクチン
|
CN109071648B
(zh)
|
2015-10-23 |
2022-07-19 |
辉瑞有限公司 |
抗il-2抗体及其组合物和用途
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
CA3002676A1
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
WO2017079428A1
(en)
|
2015-11-04 |
2017-05-11 |
President And Fellows Of Harvard College |
Site specific germline modification
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
WO2017112865A1
(en)
|
2015-12-22 |
2017-06-29 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
PL3405212T3
(pl)
|
2016-01-19 |
2020-11-16 |
Pfizer Inc. |
Szczepionki przeciwnowotworowe
|
JP2019506398A
(ja)
|
2016-01-21 |
2019-03-07 |
ファイザー・インク |
上皮増殖因子受容体変異体iiiおよびcd3の単一および二重特異性抗体およびそれらの使用
|
WO2017136685A1
(en)
|
2016-02-03 |
2017-08-10 |
President And Fellows Of Harvard College |
Methods of treating of inflammatory bowel disease and parasite infection
|
AU2017221441A1
(en)
|
2016-02-17 |
2018-10-04 |
Children's Medical Center Corporation |
FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
|
CN110753755B
(zh)
|
2016-03-21 |
2023-12-29 |
丹娜法伯癌症研究院 |
T细胞耗竭状态特异性基因表达调节子及其用途
|
US11020160B2
(en)
|
2016-03-21 |
2021-06-01 |
Warsaw Orthopedic, Inc. |
Surgical injection system and method
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
TWI780070B
(zh)
|
2016-09-20 |
2022-10-11 |
德商百靈佳殷格翰維美迪加股份有限公司 |
新穎之啟動子
|
CA3036386A1
(en)
|
2016-09-20 |
2018-03-29 |
Boehringer Ingelheim Vetmedica Gmbh |
Canine adenovirus vectors
|
CN110072546B
(zh)
|
2016-09-20 |
2023-10-31 |
勃林格殷格翰动物保健有限公司 |
新的猪流感疫苗
|
EP3515559A4
(en)
|
2016-09-20 |
2020-07-15 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS
|
JP6952112B2
(ja)
|
2016-09-20 |
2021-10-20 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH |
新規なehv挿入部位orf70
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
BR112019009133A2
(pt)
|
2016-11-03 |
2019-07-16 |
Boehringer Ingelheim Vetmedica Gmbh |
vacina contra o parvovírus suíno
|
MX2019005136A
(es)
|
2016-11-03 |
2019-06-20 |
Boehringer Ingelheim Vetmedica Gmbh |
Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
WO2018087720A1
(en)
|
2016-11-14 |
2018-05-17 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
EA201991762A1
(ru)
|
2017-01-30 |
2020-01-23 |
Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. |
Вакцины против коронавируса свиней
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
WO2018157154A2
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Novel codon-optimized cftr mrna
|
WO2018158658A1
(en)
|
2017-03-03 |
2018-09-07 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
EP4186888A1
(en)
|
2017-03-15 |
2023-05-31 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
SI3596042T1
(sl)
|
2017-03-15 |
2022-04-29 |
Modernatx, Inc. |
Kristalne oblike amino lipidov
|
WO2018167621A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
EP3610010A4
(en)
|
2017-04-14 |
2021-02-24 |
Kodiak Sciences Inc. |
COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
|
MA49138A
(fr)
|
2017-05-16 |
2020-03-25 |
Translate Bio Inc |
Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
|
WO2018220584A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
US11820822B2
(en)
|
2017-06-06 |
2023-11-21 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
|
US10650911B2
(en)
|
2017-06-13 |
2020-05-12 |
Bostongene Corporation |
Systems and methods for generating, visualizing and classifying molecular functional profiles
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
CN110869047A
(zh)
|
2017-07-12 |
2020-03-06 |
勃林格殷格翰动物保健美国有限公司 |
塞内卡病毒a免疫原性组合物及其方法
|
CA3069179A1
(en)
|
2017-07-13 |
2019-01-17 |
Massachusetts Institute Of Technology |
Targeting the hdac2-sp3 complex to enhance synaptic function
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
CN111315359A
(zh)
|
2017-08-31 |
2020-06-19 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
MX2020003071A
(es)
|
2017-09-23 |
2020-07-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Sistema de expresion de paramyxoviridae.
|
WO2019070161A2
(en)
|
2017-10-04 |
2019-04-11 |
Opko Pharmaceuticals, Llc |
ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER
|
WO2019092027A1
(en)
|
2017-11-09 |
2019-05-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Sapelovirus immunogenic compositions and uses thereof
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
EP3746483A1
(en)
|
2018-02-01 |
2020-12-09 |
Pfizer Inc |
Chimeric antigen receptors targeting cd70
|
CN111936519A
(zh)
|
2018-02-01 |
2020-11-13 |
辉瑞公司 |
对cd70具有特异性的抗体及其用途
|
AR115256A1
(es)
|
2018-02-23 |
2020-12-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
BR112020019268A2
(pt)
|
2018-03-19 |
2021-01-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Novo ehv com ul18 e/ou ul8 inativados
|
EP3768326A1
(en)
|
2018-03-19 |
2021-01-27 |
Boehringer Ingelheim Vetmedica GmbH |
Ehv insertion site ul43
|
CN112088013A
(zh)
|
2018-03-26 |
2020-12-15 |
勃林格殷格翰动物保健美国有限公司 |
制备免疫原性组合物的方法
|
CA3100829A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
GB201811382D0
(en)
|
2018-07-11 |
2018-08-29 |
Taylor John Hermon |
Vaccine
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
TW202026010A
(zh)
|
2018-09-20 |
2020-07-16 |
德商百靈佳殷格翰維美迪加股份有限公司 |
抗豬流行性下痢之鼻內載體疫苗
|
KR20210062015A
(ko)
|
2018-09-20 |
2021-05-28 |
베링거잉겔하임베트메디카게엠베하 |
변형된 pedv 스파이크 단백질
|
JP2022517029A
(ja)
|
2019-01-15 |
2022-03-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
変異したインターロイキン-34(il-34)ポリペプチドおよび治療におけるその使用
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
JP2022538499A
(ja)
|
2019-07-03 |
2022-09-02 |
ボストンジーン コーポレイション |
サンプル調製、サンプルシークエンシング、およびシークエンシングデータのバイアス補正と品質管理のためのシステムならびに方法
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
EP4041312A4
(en)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
METHOD FOR TREATING AN EYE DISORDER
|
EP4041773A1
(en)
|
2019-10-11 |
2022-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
US11858962B2
(en)
|
2020-02-06 |
2024-01-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Polypeptides useful for detecting anti-rhabdovirus antibodies
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
EP4136219A1
(en)
|
2020-04-16 |
2023-02-22 |
Par'Immune SAS |
28 kda gst proteins from schistosoma for the treatment of vasculitis
|
US20230181750A1
(en)
|
2020-05-06 |
2023-06-15 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
US20230285357A1
(en)
|
2020-05-27 |
2023-09-14 |
The Regents Of The University Of California |
Compositions and methods for transdifferentiating cells
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
JP2022025558A
(ja)
|
2020-07-29 |
2022-02-10 |
学校法人帝京大学 |
miR-96-5pインヒビターとそれを含有する医薬組成物
|
CA3190227A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
KR20230082653A
(ko)
|
2020-10-05 |
2023-06-08 |
베링거잉겔하임베트메디카게엠베하 |
로타바이러스에 대한 백신 접종에 유용한 융합 단백질
|
CN116438202A
(zh)
|
2020-10-05 |
2023-07-14 |
勃林格殷格翰动物保健美国有限公司 |
包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
US20240029829A1
(en)
|
2020-12-04 |
2024-01-25 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US20240158864A1
(en)
|
2021-01-25 |
2024-05-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
US20220372580A1
(en)
|
2021-04-29 |
2022-11-24 |
Bostongene Corporation |
Machine learning techniques for estimating tumor cell expression in complex tumor tissue
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023012627A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
US20230245479A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|
WO2023194913A1
(en)
|
2022-04-05 |
2023-10-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Immunogenic composition useful for vaccination against rotavirus
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|